PAH

Dermatology

Prevalence

5.0 / 100K

28 drugs in development·15 companies·3 clinical trials

Drug Pipeline by Phase

Approved(15)

Drug	Company
adcirca	ELI LILLY & Co (LLY)
Adcirca	UNITED THERAPEUTICS Corp (UTHR)
ambrisentan	Mylan II B.V. (MYL)
drug application	Liquidia Corp (LQDA)
epoprostenol	Mylan II B.V. (MYL)
letairis	GILEAD SCIENCES, INC. (GILD)
macitentan	Mylan II B.V. (MYL)
Orenitram	UNITED THERAPEUTICS Corp (UTHR)
Remodulin	UNITED THERAPEUTICS Corp (UTHR)
Remunity Pump for Remodulin	UNITED THERAPEUTICS Corp (UTHR)
revatio	Viatris Inc (VTRS)
treprostinil	Teva Pharmaceutical Industries Limited (TEVA)
tyvaso dpi	MANNKIND CORP (MNKD)
Winrevair	Merck & Co., Inc. (MRK)
YUTREPIA	Liquidia Corp (LQDA)

Phase 3(4)

Drug	Company
ikt-001	Inhibikase Therapeutics, Inc. (IKT)
ikt-001pro	Inhibikase Therapeutics, Inc. (IKT)
Ralinepag	UNITED THERAPEUTICS Corp (UTHR)
Selumetinib Oral Capsule	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(4)

Drug	Company
Cabozantinib Oral Tablet	UNITED THERAPEUTICS Corp (UTHR)
cibotercept (KER-012)	Keros Therapeutics, Inc. (KROS)
oral treprostinil	UNITED THERAPEUTICS Corp (UTHR)
regn13335	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 1(1)

Drug	Company
Atovaquone Oral Suspension	UNITED THERAPEUTICS Corp (UTHR)

Preclinical(3)

Phase 4(1)

Drug	Company
Initiating daily oral PrEP during pregnancy	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 28 drugs in development for PAH across 15 companies.

There are 3 clinical trials targeting PAH tracked by BioSniper.

The estimated prevalence of PAH is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.